Anti-PD-L1 antibodies
AssigneeAgency for Science, Technology and Research
InventorsCheng-I Wang, Hsueh Ling Janice Oh, Siok Ping Yeo
Life of this patent
Estimating the term…
Abstract
Anti-PD-L1 antibodies are disclosed. Also disclosed are pharmaceutical compositions comprising such antibodies, and uses and methods using the same.
Claims20
A method of treating cancer, comprising administering an antibody or antigen binding fragment to a patient suffering from a cancer, wherein the antibody or antigen binding fragment binds to PD-L1, and comprises:
- at least one light chain variable region incorporating the following CDRs:
- LC-CDR1:
- TGSSSNIGAGYDVH (SEQ ID NO:18)
- LC-CDR2:
- GNSNRPS (SEQ ID NO:19)
- LC-CDR3:
- QSYDSSLSGSYVV (SEQ ID NO:20);
- and
- at least one heavy chain variable region incorporating the following CDRs:
- HC-CDR1:
- SYAIS (SEQ ID NO:21)
- HC-CDR2:
- RIIPILGIANYAQKFQG (SEQ ID NO:22)
- HC-CDR3:
- SGHGYSYGAFDY (SEQ ID NO:25).
A method of treating cancer, comprising administering an antibody or antigen binding fragment to a patient suffering from a cancer, wherein the antibody or antigen binding fragment binds to PD-L1, and comprises:
- a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:8 or 35, and
- the light chain variable region comprising the amino acid sequence of SEQ ID NO:4.
A method of treating cancer in a subject, comprising:
- culturing T cells obtained from a blood sample from a subject having a cancer in the presence of an antibody or antigen binding fragment which binds to PD-L1 to expand a T cell population;
- and
- administering the expanded T cell population to the subject;
- wherein the antibody or antigen binding fragment which binds to PD-L1 comprises:
- at least one light chain variable region incorporating the following CDRs:
- LC-CDR1:
- TGSSSNIGAGYDVH (SEQ ID NO:18)
- LC-CDR2:
- GNSNRPS (SEQ ID NO:19)
- LC-CDR3:
- QSYDSSLSGSYVV (SEQ ID NO:20);
- and
- at least one heavy chain variable region incorporating the following CDRs:
- HC-CDR1:
- SYAIS (SEQ ID NO:21)
- HC-CDR2:
- RIIPILGIANYAQKFQG (SEQ ID NO:22)
- HC-CDR3:
- SGHGYSYGAFDY (SEQ ID NO:25).
Dependencies are inferred from the claim text.